Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $149.50M | $-74.62M | $-1.18 |
| 2024 | $148.34M | $-66.97M | $-1.07 |
| 2023 | $57.19M | $-9.06M | $-0.15 |
| 2022 | $150.02M | $-119.76M | $-1.95 |
| 2021 | $75.64M | $-202.12M | $-3.37 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.29 per share
Typical surprise +3.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.31 vs $-0.08beat
- Wed, May 13$-0.58 vs $-0.57miss
- Mon, Mar 9$-0.22 vs $-0.42beat
- Wed, Nov 12$0.27 vs $-0.48beat
- Thu, Aug 14$-0.57 vs $-0.59beat
- Tue, May 13$-0.65 vs $-0.61miss
Estimates and results for MGNX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
MGNXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newszacks.com·1d ago·Negative
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.
View source ↗